Included in the formulation
АТХ:D.11.A.X Other preparations for the treatment of skin diseases
Pharmacodynamics:With external application stimulates the development of granulation tissue and regeneration processes, promotes epithelization; accelerates cleansing, reduces the risk of infection, reduces intoxication of the body, improves the course of the wound process.
Spectrum of antimicrobial action: bacteriostatic effect against many gram-negative and gram-positive bacteria, including Pseudomonas aeruginosa and some anaerobic microorganisms.
Pharmacokinetics:The pharmacokinetics of sodium alginate, calcium gluconate and fenozanoic acid with local application not studied. Mafenide It is absorbed from the skin surface with local application (even through a scab) in a small amount. Rapidly metabolized into non-toxic p-carboxybenzenesulfonylamide, which does not have antibacterial activity, but inhibits carbonic anhydrase. Eliminated by the kidneys in the form of metabolites, in urine in unchanged form is not determined.
Indications:Superficial burns I and II-a degree, long-term non-healing trophic ulcers of any etiology in II phase of the wound process.
XII.L80-L99.L98.4 Chronic skin ulcer, not elsewhere classified
XIX.T08-T14.T14.1 Open wound of unspecified area of the body
XIX.T20-T32.T30 Thermal and chemical burns, unspecified
Contraindications:It is not recommended to use in case of threat of anaerobic infection (infection with bacteria that can exist in the absence of oxygen) of the wound.
Carefully:It is not recommended to apply mafenide more than 20% of the body surface.
Pregnancy and lactation:With topical application mafenide absorbed and enters the systemic circulation. Mafenide can displace bilirubin from the bonds with the fetal blood plasma, which increases the risk of developing nuclear jaundice. Do not use women immediately before delivery. There is no information on the penetration of mafenide into breast milk. FDA recommendation category C (mafenide).
Dosing and Administration:Nakozhno, put directly after the toilet burn wound or after surgical treatment and fix gauze bandage.
Side effects:Transient burning sensation.
Interaction:Not described.
Sodium alginate is pharmaceutically incompatible with acridine derivatives,gentian violet, calcium salts, phenylmercury acetate and phenylmercury nitrate, ethanol at a concentration of more than 5% and salts of heavy metals.
Calcium gluconate is not pharmaceutically compatible with carbonates, salicylates, sulfates (forms insoluble or sparingly soluble salts).
Special instructions:With the threat of anaerobic infection of the wound, the use of the drug is inappropriate.